Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Porter

Showing results (41-50 of 199) with videos related to

Pageof 20
Sort By:
Blood Advances|March 15, 2018
Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell diseaseHitomi Hosoya, Jeffrey Levine, Peter Abt, et al.
Annual Review of Medicine|November 27, 2013
Chimeric antigen receptor therapy for cancerDavid M Barrett, Nathan Singh, David L Porter, et al.
The American Journal of Managed Care|September 6, 2002
Recombinant human erythropoietin usage in a large academic medical centerJoshua H Bilenker, Richard Demers, David L Porter, et al.
The Journal of Antimicrobial Chemotherapy|April 18, 2015
Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipientsAlex Ganetsky, Todd A Miano, Mitchell E Hughes, et al.
Science Translational Medicine|August 12, 2011
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaMichael Kalos, Bruce L Levine, David L Porter, et al.
JCO Oncology Practice|May 13, 2025
Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and NeurotoxicityLucy Andersen, Ryan J Quinn, Heather Difilippo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2017
Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease ProphylaxisAustin P Huffman, Lee P Richman, Lisa Crisalli, et al.
Seminars in Oncology Nursing|August 30, 2025
Factors Related to Long-Term Caregiving Burden Among Chimeric Antigen Receptor (CAR) T-Cell Recipients and Their Informal CaregiversLucy P Andersen, Ryan J Quinn, Heather Difilippo, et al.
Transplantation and Cellular Therapy|May 23, 2025
Long-Term Financial Toxicity After CAR T-Cell Therapy Among Patients in Remission and Their CaregiversLucy P Andersen, Ryan J Quinn, Heather Difilippo, et al.
Transplantation and Cellular Therapy|November 27, 2024
Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A ReviewConnor B Grady, Yimei Li, Shannon L Maude, et al.
Pageof 20

Showing results (41-50 of 199) with videos related to

Sort By:
Pageof 20
Blood Advances|March 15, 2018
Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell diseaseHitomi Hosoya, Jeffrey Levine, Peter Abt, et al.
Annual Review of Medicine|November 27, 2013
Chimeric antigen receptor therapy for cancerDavid M Barrett, Nathan Singh, David L Porter, et al.
The American Journal of Managed Care|September 6, 2002
Recombinant human erythropoietin usage in a large academic medical centerJoshua H Bilenker, Richard Demers, David L Porter, et al.
The Journal of Antimicrobial Chemotherapy|April 18, 2015
Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipientsAlex Ganetsky, Todd A Miano, Mitchell E Hughes, et al.
Science Translational Medicine|August 12, 2011
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaMichael Kalos, Bruce L Levine, David L Porter, et al.
JCO Oncology Practice|May 13, 2025
Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and NeurotoxicityLucy Andersen, Ryan J Quinn, Heather Difilippo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2017
Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease ProphylaxisAustin P Huffman, Lee P Richman, Lisa Crisalli, et al.
Seminars in Oncology Nursing|August 30, 2025
Factors Related to Long-Term Caregiving Burden Among Chimeric Antigen Receptor (CAR) T-Cell Recipients and Their Informal CaregiversLucy P Andersen, Ryan J Quinn, Heather Difilippo, et al.
Transplantation and Cellular Therapy|May 23, 2025
Long-Term Financial Toxicity After CAR T-Cell Therapy Among Patients in Remission and Their CaregiversLucy P Andersen, Ryan J Quinn, Heather Difilippo, et al.
Transplantation and Cellular Therapy|November 27, 2024
Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A ReviewConnor B Grady, Yimei Li, Shannon L Maude, et al.
Pageof 20